Summary
Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response to chemotherapy. However, ER+ tumours seem to grow more slowly than ER- ones and the response to chemotherapy tends to be longer in ER+ patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonnadonna G, Di Fronzo G, Tancini G (1979) Oestrogen receptors (ER) and response to chemotherapy in advanced and early breast cancer. Proc Am Soc Clin Oncol 20:359
Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292
Hilf R, Feldstein ML, Gibson SL, Savlov ED (1979) Does oestrogen receptor status have prognostic value for recurrence or chemotherapy response in breast cancer? Proc Am Soc Clin Oncol 20:298
Jonat W, Maas H (1978) Some comments on the necessity of receptor determination in human breast cancer. Cancer Res 38:4305
Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ (1978) Oestrogen receptors and responses to chemotherapy and hormonal therapy in advanced cancer. N Engl J Med 299:1330
King RJB, Redgrave S, Hayward JL, Millis RR, Rubens RD (1979) The measurement of receptors for oestradiol and progesterone in human breast tumours. In: Steroid receptor assays in breast tumours: methodological and clinical aspects. King, RJB (ed.). Alpha Omega Alpha Publishing, Cardiff, p. 55
Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Airken SC, Warren R (1978) The relation between oestrogen receptors and response rate to cytotoxic chemotherapy in netastatic breast cancer. N Engl J Med 298:1223
Marsland TA, Rosenbaum C, Stolbach LL, Cohen JL (1979) Oestrogen receptors (ER) and chemotherapy (CT) in breast cancer. Proc Am Soc Clin Oncol 20:367
Meyer JS, Rao BR, Stevens SC, White WL (1977) Low incidence of oestrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40:2290
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomised clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 35:1
Rosner D, Nemoto T (1979) A randomised study of 2 and 3 drug regimen in relation with oestrogen receptors in metastatic breast cancer. Proc Am Assoc Cancer Res 20:46
Rubens RD, Knight RK, Hayward JL (1975) Chemotherapy of advanced breast cancer: a controlled randomised trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32:730
Rubens RD, Begent RHJ, Knight RK, Sexton S, Hayward JL (1978) Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42:1680
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rubens, R.D., King, R.J.B., Sexton, S. et al. Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer. Cancer Chemother. Pharmacol. 4, 43–45 (1980). https://doi.org/10.1007/BF00255457
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255457